EX-103

N/A

Report date: 2026/03/19 17:23:42

Base Information

Drug NameEX-103

Drug Alias NameEX-103EX103

ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Multispecific monoclonal antibody > Bispecific monoclonal antibodyBiologics > T cell engagers

Mechanisms of ActionAnti-CD20T cell surface glycoprotein CD3 inhibitors

TargetsB-lymphocyte antigen CD20T cell surface glycoprotein CD3

Therapy Area/IndicationsArthritis, RheumatoidLymphoma, Non-HodgkinLeukemia, Lymphocytic, Chronic, B-Cell

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryUnited StatesMainland China

CombinationsNo

Global Highest StatusPhase 2 Clinical

Highest Status in ChinaPhase 2 Clinical

Originator CompaniesGuangzhou Excelmab Inc

China Registration ClassClass 1 therapeutic biologic in China

Develop Information

Active CompaniesGuangzhou Excelmab Inc

Inactive CompaniesN/A

Active IndicationsArthritis, RheumatoidLymphoma, Non-HodgkinLeukemia, Lymphocytic, Chronic, B-Cell

Inactive IndicationsN/A

Other Information

ATC CodeN/A